Agenda 2021



Current Approaches to the Management of Patients with Follicular Lymphoma
The Future of Recurrent DLBCL Treatment: CAR-T Cell vs Novel Agents
The Role of ADCs and ICIs in the Treatment of Hodgkin Lymphoma
Standard Regimens and Novel Agents for Mantle Cell Lymphoma
Updates in T Cell Lymphoma Treatment
Treatment Approach for Marginal Zone Lymphoma and Waldenstrom's Macroglobulinemia

Chronic Lymphocytic Leukemia

Strategies for Initial Therapy
Sequencing Regimens for Patients with Recurrent CLL
Sorting Through BTKi and Novel Agents
Managing Patients with Richter's Transformation

Acute Leukemia

The Change in Treatment Paradigm for AML Maintenance
Is the Future of AML Oral Therapy?
Debate: Should MRD+ AML Proceed with Transplant?
Approaches to Older Adult and AYA with ALL
Approach to Ph+ and Ph-like ALL

Myelodysplastic Syndrome & Myeloproliferative Neoplasms

Approaches to Initial Treatment of High-Risk MDS
Novel Therapies for MPNs with a Focus on CMMoL
Toxicity Mitigation in CML Therapy

Multiple Myeloma

CAR-T: Are We Ready to Stop Stem Cell Transplant?
Frontline Therapy in Myeloma for Transplant Eligible/Ineligible Patients
Emerging Therapies in Myeloma
Treating the Relapsed Patient
Making Sense of Imaging in Myeloma

Special Topics in Hematologic Malignancies

COVID-19 Update: Who Should Get the Vaccine and How to Manage COVID-19 and Cancer?
Interdisciplinary Management of Adverse Events
Disparity in Hematologic Malignancies
Considerations on Next Generation Sequencing